HistoryThis section has been translated automatically.
DefinitionThis section has been translated automatically.
Rare, acquired, blistering autoimmune disease with antibodies against type VII collagen, the main component of the "anchoring fibrils" in the dermoepidermal junction zone. The disease can occur after viral infections, as a paraneoplastic syndrome, also after autoimmunological reactions (e.g. after autologous stem cell transplantation).
You might also be interested in
ClassificationThis section has been translated automatically.
A distinction is made between 3 clinical variants:
- Classical, acrally accentuated mechano-bullous form (blistering only at mechnaically stressed sites).
- Generalized, inflammatory form, clinically corresponding to bullous pemphigoid (blistering ubiquitous).
- Localized form with the appearance of scarring pemphigoid.
Occurrence/EpidemiologyThis section has been translated automatically.
Incidence in Western Europe: 0.25-1.0/1.0 million inhabitants/year. No ethnic clustering.
EtiopathogenesisThis section has been translated automatically.
Blister-forming autoimmune disease; autoantigen is collagen type VII, which is the main component of the anchoring fibrils of the papillary dermis. The antibodies bind to the NC1 domain of collagen type VII.
ManifestationThis section has been translated automatically.
Occurrence is possible at any age, usually between the 40th and 60th year of life. Rarely also occurring in children. m:w=1:1;
Clinical featuresThis section has been translated automatically.
- In the classic form of the disease, tight, non-inflammatory blisters of various sizes are found, predominantly on mechanically traumatized skin regions (especially hands, elbows, feet, knees) and, in rare cases, on the oral mucosa. Occasionally, the affected areas heal with skin atrophy or milia, hyper- and hypopigmentation.
- A second clinical variant (30% of cases) presents as a generalized, pruritic, inflammatory disease with the appearance of bullous pemphigoid.
- A third variant presents as localized Brunsting-Perry scarring pemphigoid.
- A fourth variant has been described under the picture of a linear IgA dermatosis, with blistering of the face, partly under the picture of impetigo contagiosa.
Extracutaneous manifestations: In rare cases, formation of esophageal or urethral strictures.
Reviews have identified an association between epidermolysis bullosa acquisita (EBA) and inflammatory bowel disease (IBD). In 42 coincident cases, Crohn's disease (K50.9) was detected 35x and ulcerative colitis (K51.9) 7x. In most cases, inflammatory bowel disease preceded the skin lesions (Reddy H et al 2013). Note: The antigen of EBA (collagen type VII) is also expressed in the intestinal mucosa between epithelium and stratum proprium.
HistologyThis section has been translated automatically.
Subepidermal blistering. Edema of the dermis. Bulky, diffusely arranged, predominantly neutrophil infiltrates in the upper dermis, in the case of gaping blood and lymph vessels. Diagnosis: Diffuse, superficial, predominantly neutrophil dermatitis with subepidermal blistering.
Electron microscopy: fissure formation in the dermo-epidermal junction zone in the area of the sublamina densa zone. Reduction of the number of anchoring fibrils.
Direct ImmunofluorescenceThis section has been translated automatically.
Linear IgG andC3 deposition in the basement membrane zone. Pattern corresponding to the localization of collagen VII in the sublamina densa zone of the skin.
At high magnification, a typical pattern of IgG deposits can be detected, which is typical for EBA: the so-called "U-serrated pattern" (Br J Dermatol 2004). This is an important diagnostic criterion, since circulating autoantibodies can be detected in only about 50-60% of EBA patients. With the detection of the "U-serrated pattern" in direct IF, the diagnosis of EBA is unequivocal.
In immunoelectron microscopy IgG deposits below the lamina densa, partly also at the anchoring fibrils. However, this method is only used by very few centers and is reserved for special cases.
Indirect immunofluorescenceThis section has been translated automatically.
In approximately 50-60% of patients, IgG and/or IgA autoantibodies against type VII collagen can be detected serologically. Detection is initially by indirect IF using salt-split skin as substrate. In EBA, the autoantibodies bind to the bottom of the artificial bladder. However, this is not conclusive for EBA, as p200 antigen and laminin-332 are also expressed at the bottom of the bladder.
ELISA (NC1/NC2) or immunochip (with cells expressing COL7) can be used to detect collagen 7-specific antibodies. Also possible is detection by Western blot on dermal extract with detection of a band at 290 kD.
DiagnosisThis section has been translated automatically.
Clinic and detection of a u-serrated pattern in direct IF confirm the diagnosis.
If the pattern does not present in the direct IF, the diagnosis can be made in the case of linear Ig/C3 deposits in the direct IF as follows:
- Serological detection of type VII collagen specific autoantibodies.
- Immunoelectron microscopy
Differential diagnosisThis section has been translated automatically.
TherapyThis section has been translated automatically.
External therapyThis section has been translated automatically.
Internal therapyThis section has been translated automatically.
Systemic therapy is indicated in cases of generalization or mucosal involvement. Only some patients (especially with a strong inflammatory component) respond well to monotherapy with systemic glucocorticoids, medium dosage (60-80 mg/day prednisone equivalent). Therefore, the combination of glucocorticoids with the following immunosuppressants should be sought:
- Azathioprine (e.g. Imurek) 1-2 mg/kg bw/day.
- Cyclophosphamide (e.g. Endoxan) 50 mg/day
- DADPS (e.g. dapsone fatol) 100-150 mg/day
- Ciclosporin A (e.g. Sandimmun) 5-7 mg/kg bw/day
- Colchicine (e.g. Colchicine Dispert Drg.) 0.5-2 mg/day.
Therapy trial is also possible with vitamin E (e.g. Evit Kps.) high dose 600-1200 mg/day. Under this therapy complete healing is described in individual cases, but the improvement occurs only over a long period of time.
Newer therapeutic approaches:
- IVIG: Immunoglobulins (e.g. Pentaglobin) 5 ml/kg bw/day i.v. for 3-7 consecutive days in combination with e.g. Prednisolon or Ciclosporin A treatment should lead to better results. According to literature, intravenous immunoglobulins seem to have a therapeutic effect only initially. Long-term improvements have not been described among them.
- Plasmapheresis may reduce the maintenance dose of glucocorticoids and immunosuppressants as an adjunctive measure.
ProphylaxisThis section has been translated automatically.
Preventive; if possible, no exceptional mechanical stress on the skin.
Note(s)This section has been translated automatically.
LiteratureThis section has been translated automatically.
- Bari B et al (1996) Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol 34: 781-784
- Bauer JW (1999) Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol 141: 887-892
- Busch JE et al. (2007) Epidermolysis bullosa acquisita and neuroendocrine pancreatic carcinoma coincidence or pathogenetic association. JDDG 10: 916-918
- Caldwell JB et al (1994) Epidermolysis bullosa acquisita - Efficacy of high dose intravenous immunoglobulins. J Am Acad Derm 31: 827-828
- Elliot GT (1895) Two cases of epidermolysis bullosa. J Cutan Genitourinary Dis (Chicago) 13: 10-18
- Goebeler M, Zillikens D (2003) Blistering autoimmune diseases of childhood]. dermatologist 54: 14-24
- Hertl M, Schuler G (2002) Bullous autoimmune dermatoses. 1: Classification. dermatologist 53: 207-219
- Jappe U et al. (2000) Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity. Br J Dermatol 142: 517-520
Kasperkiewicz M et al(2016) Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. J Invest Dermatol 136:24-33.
Ludwig RJ et al (2017) Mechanisms of Autoantibody-Induced Pathology.Front Immunol 8:603.
Mohr C et al (1995) Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 132: 824-826
- Niederau D (1995) Epidermolysis bullosa acquisita - Successful treatment with dapsone in combination with glucocorticosteroids. Z Hautkr 70: 454-455
- Reddy H et al (2013) Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of theliterature
. Clin Exp Dermatol 38:225-229; quiz 229-30.
- Roenigk HH et al (1971) Epidermolysis bullosa acquisita: Reports of three cases and review of all published cases. Arch Dermatol 103: 1-10
- Schmidt E (2002) Childhood epidermolysis bullosa acquisita: a novel variant with reactivity to all three structural domains of type VII collagen. Br J Dermatol 147: 592-597
- Schmidt E et al (2013) Pemphigoid diseases. Lancet 381:320-332.
- Trigo-Guzman FX et al (2003) Epidermolysis bullosa acquisita in childhood. J Dermatol 30: 226-229
- Vodegel RM (2003) Anti-epiligrin cicatricial pemphigoid and epidermolysis bullosa acquisita: differentiation by use of indirect immunofluorescence microscopy. J Am Acad Dermatol 48: 542-547
- Vodegel RM et al (2002) IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol 47: 919-925
- Woodley DT et al (1984) Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310: 1007-1013
Incoming links (9)Autoimmune dermatoses, bullous; Bullosis diabeticorum; Bullous systemic lupus erythematosus; Linear IgA dermatosis; Pancreatic diseases and skin; Pemphigoid bullous localized; Porphyria cutanea tarda; Rituximab; Salt split skin investigation;
Outgoing links (31)Adverse drug reactions of the skin; Atrophy of the skin (overview); Azathioprine; Chronic lymphocytic thyroiditis; Ciclosporin a; Colchicine; Collagens; Crohn disease, skin alterations; Cyclophosphamide; Dadps; ... Show all
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.